Hunt EB, Ward C, Power S, Sullivan A, Pearson J, Lapthorne S, O'Byrne PM,
Eustace J, Plant BJ, Maher MM, MacSharry J, Murphy DM.

[The potential role of aspiration in the asthmatic airway.](#)

Chest 2017, 151(6), 1272-1278.

Copyright:

© 2017. This manuscript version is made available under the [CC-BY-NC-ND 4.0 license](#)

DOI link to article:

<http://dx.doi.org/10.1016/j.chest.2017.03.005>

Date deposited:

06/06/2017

Embargo release date:

11 March 2018

This work is licensed under a
[Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence](#)

Accepted Manuscript

The potential role of aspiration in the asthmatic airway

Eoin B. Hunt, MD, Chris Ward, PhD, Stephen Power, MD, Ashley Sullivan, Bsc, Jeffrey Pearson, PhD, Susan Lapthorne, PhD, Paul M. O'Byrne, MD FCCP, Joseph Eustace, MD, Barry J. Plant, MD, Michael M. Maher, MD, John MacSharry, PhD, Desmond M. Murphy, MD FCCP

PII: S0012-3692(17)30365-3

DOI: [10.1016/j.chest.2017.03.005](https://doi.org/10.1016/j.chest.2017.03.005)

Reference: CHEST 987

To appear in: *CHEST*

Received Date: 15 December 2016

Revised Date: 10 February 2017

Accepted Date: 1 March 2017

Please cite this article as: Hunt EB, Ward C, Power S, Sullivan A, Pearson J, Lapthorne S, O'Byrne PM, Eustace J, Plant BJ, Maher MM, MacSharry J, Murphy DM, The potential role of aspiration in the asthmatic airway, *CHEST* (2017), doi: 10.1016/j.chest.2017.03.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The potential role of aspiration in the asthmatic airway.

Eoin B. Hunt MD^{1,6}, Chris Ward PhD², Stephen Power MD³, Ashley Sullivan Bsc⁴, Jeffrey Pearson PhD², Susan Lapthorne PhD^{1,4}, Paul M. O'Byrne MD FCCP⁵, Joseph Eustace MD⁶, Barry J. Plant MD^{1,6}, Michael M. Maher MD^{3,6}, John MacSharry PhD^{4*}, Desmond M. Murphy MD FCCP^{1,6*}

The Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland¹.

The Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK²

The Department of Radiology, Cork University Hospital, Cork, Ireland³.

The APC Microbiome Institute, Schools of Medicine and Microbiology, University College Cork, Ireland⁴

The Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada⁵

The HRB Clinical Research Facility, University College Cork, Cork, Ireland⁶.

*= Joint Senior Authors

Corresponding Author:

Dr. Desmond M Murphy,

Consultant Respiratory Physician,

The Department of Respiratory Medicine,

Cork University Hospital,

Cork,

Ireland.

Email: desmond.murphy@hse.ie

Conflicts of Interest: BP has received speaker honoraria and consultancy fees from Gilead, Novartis, Vertex, Raptor, Pfizer and Menarini Pharmaceuticals. DMM has

been awarded an APC grant from University College Cork and funding from the Wilton Respiratory Research Fund to support this research. He is the past recipient of an ERS fellowship. He has received fees for consultancy work from Novartis, Bayer, AstraZeneca, Menarini, Nycomed, Gilead, Boehringer Ingelheim, Teva, Rowex and Mundipharma. He has received speaker's fees from Pfizer, Menarini, GSK, Bayer, MSD and Novartis. He has traveled to international symposia as a guest of Boehringer Ingelheim and Novartis. All others declare no conflicts of interest.

Abstract

Background: Many asthmatics remain sub-optimally controlled despite current treatments. Reasons include comorbidities that could aggravate asthma, including gastro-esophageal reflux (GER). We aimed to investigate whether aspiration occurs in asthmatic patients and if so does it correlate with asthma control.

Methods: Patients had ACQ-7, FeNO, and spirometry performed to characterize their level of asthma control. Barium swallow with provocation was performed to assess for predisposition to aspiration. Patients underwent bronchoscopic investigation, with bronchoalveolar lavage (BAL) pepsin measured as a marker of aspiration.

Results: Seventy-eight patients stratified by disease severity (GINA) into mild (35.8%), moderate (21.7%) and severe (42.3%) were studied. Pepsin was detectable in BAL in 46/78 (58.9%). There were no differences between pepsin levels in patients with different disease severity. Furthermore, no significant associations were seen between pepsin level and measures of asthma control, FEV₁, ACQ or

exacerbation frequency. Similarly no associations were found with adjustments for smoking history, BMI, proton pump inhibitor use, eosinophil count or IgE. When stratified into eosinophilic or neutrophilic asthmatic populations based on BAL there was no relationship to detected pepsin concentrations. A positive barium swallow (seen in 33/60 patients) did not correlate with BAL pepsin level and we found no significant association between barium swallow result and ACQ, GINA, exacerbation frequency or FEV₁ using either univariate or multivariate analyses.

Conclusion: Our study suggests that the importance of aspiration on current asthma symptom control and exacerbation rate may be over-stated. However, our study did not address the role of aspiration and future risk of exacerbation.

INTRODUCTION

Approximately 10% of patients with asthma have persisting symptoms and exacerbations despite combination therapy with long-acting β agonists and inhaled corticosteroids¹. This inadequate therapeutic response may be due to medication-refractory asthma or to difficult-to-manage asthma arising from confounding issues such as poor inhaler technique, poor adherence or coexisting comorbid disease¹⁻³. Adherence to medication may be compounded by the fact that some patients may demonstrate a reasonable inhaler technique when directly observed, but may be careless in their inhaler use on a day-to-day basis⁴⁻⁶. Comorbidities and complicating conditions such as rhinosinusitis, gastroesophageal reflux (GER) and obesity also play significant roles in uncontrolled asthma¹. □

Several risk factors have been identified with a more severe asthma phenotype. These include female sex, obesity, and tobacco exposure, some of which are also risk factors for GER⁷. Previous studies suggest that GER, although often asymptomatic, is common in the asthmatic population⁸, but it is unclear whether any association between GER and asthma severity is the result of confounding or due to a direct independent effect. Trials examining the potential therapeutic use of proton pump inhibitors (PPI's) in asthma have had mixed results⁹⁻¹¹. Therefore, current evidence does not support their routine use to improve clinical outcomes in asthma. However, while GER may predispose to aspiration it is not synonymous with it. In addition, treatment with PPI's reduces gastric acidity and thus acidity of reflux, but does not prevent non-acid reflux, or aspiration into the airways of at risk patients¹². If such non-acid reflux is mechanistically important then PPI's would be expected to be of limited efficacy.

Pepsin is produced in the stomach in response to substances such as CCK, gastrin, VIP, secretin and insulin. Levels of pepsin, used as a biomarker of gastric aspiration, are elevated in BAL of lung transplant recipients, and are associated with acute and chronic rejection¹⁴. Fundoplication, which reduces or prevents aspiration has been successfully employed post-lung transplant in uncontrolled studies. Successful

fundoplication has also been reported in asthmatic patients, albeit in case reports and series¹⁵.

The aim of this study was to determine the prevalence of aspiration (as defined by detectable pepsin in BAL) in a cohort of patients with mild, moderate and severe asthma. The association of BAL differential, smoking status, steroid use (oral as well as inhaled), PPI use, BMI as well as the presence of atopy, with pepsin level was also examined.

METHODS

Study approval was granted by the University College Cork's clinical research ethics committee: (ECM 4 (m) 01/10/13). After informed consent was received, 78 asthmatics were prospectively recruited from an asthma clinic in Cork University Hospital. On the morning of bronchoscopy, spirometry and a validated asthma control questionnaire (ACQ-7) were completed by enrolled subjects¹⁶. A history of exacerbations over the preceding 12-month period was ascertained and validated against both inpatient and community pharmacy prescriptions. Patients had blood drawn for peripheral eosinophil count, IgE and RAST testing for grass pollen, animal danders, house dust mite, and aspergillus. Finally testing of FeNO was performed using the NIOX MINO® device (Aerocrine AB, Sweden)¹⁷.

Bronchoscopy and BAL:

Bronchoscopy was performed under conscious sedation with patients in a semi reclined position.

BAL was obtained from the right middle lobe or lingula as a standardized 3 x 60 ml procedure. BAL pH was measured using non-bleeding pH indicator strips immediately post-bronchoscopy (Merck, Germany). The BAL sample was divided, and clinical microbiology was assessed in a standardized fashion. Differential cell counts were made on Kwik Diff™ stain (Thermo Scientific, USA) cyto-centrifuge preparations. Cell-free BAL supernatants were prepared by centrifugation (10 min, 500g, 21°C); aliquots were subsequently stored at -80°C before ELISA testing.

Pepsin ELISA

A locally developed indirect ELISA was used to measure pepsin¹³. Briefly, 100 µL of pepsin standard (pepsin from porcine gastric mucosa, Sigma) and undiluted BAL supernatants were allowed to adsorb onto a 96-well plate (Nunc MaxiSorp) in triplicate. Non-specific binding sites were blocked with 1% ELISA grade bovine serum albumin (Merck Millipore) in PBS (pH 7.4). The primary antibody was specific to porcine pepsin (Biodesign International Cat no W59117G). Secondary antibody was horse radish peroxidase-conjugated rabbit, anti-goat (Sigma). Antibodies were diluted in Tris-buffered saline (20 mM Tris base, 150 mM NaCl, pH 7.4) containing 0.1% BSA and 0.05% Tween 20. The substrate used was 2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) and the reaction was stopped with an equal volume of 1% SDS. Negative controls were performed with the omission of primary antibody.

Barium Swallow

A standard double-contrast barium swallow study was carried out with patients in both upright and supine positions. Where spontaneous GER was not demonstrated, provocation manoeuvres were employed, starting with a cough, followed by Valsalva manoeuvres, rolling the patient and the water siphon test. Secondary signs of reflux were recorded, including esophageal reflux, cricopharyngeal bars and hiatal herniae but only patients in whom reflux was demonstrated during the procedure were characterised as positive for GER¹⁸.

Statistics:

The distribution, central tendency and spread of each variable were examined using standard tabular and graphical methods. In primary analysis the association of aspiration with markers of disease severity was examined in univariate analysis using Fishers exact test and in multivariate analysis using logistic regression. Analysis was conducted using GraphPad Prism 6 (La Jolla California USA).

RESULTS:

Patient characteristics are described in Table 1. Seventy-eight patients were recruited (49 female). There were 8 current (14.8 pack years), 19 ex-smokers (15 pack years) and 51 non-smokers. There were no significant differences in smoking status across disease severity.

Thirty-two patients demonstrated positive barium studies. Twenty-six patients were on PPI's and/or H₂-antagonist therapy. Eight patients were on maintenance regimens of oral steroids at the time of testing (range 5-20mg daily). In total 63 patients underwent all investigations, with a further 15 patients undergoing all investigations except barium swallow.

Pepsin levels:

BAL pepsin was detectable in 46/78 (58.9%) patients. Peripheral eosinophilia ($>0.3 \times 10^9/\text{ml}$) was present in 26/78 (33.3%), with an elevated IgE ($>80\text{UI/ml}$) detected in 42/78 (53.8%) of patients. BAL cell differential demonstrated eosinophilia ($>1\%$) in 28/78 (35.9%), and neutrophilia ($>3\%$) in 27/78 (34.6%) (see Supplemental Figure 1)¹⁹. A significant correlation was seen between peripheral and BAL eosinophils, $r = 0.39$ ($p < 0.0005$).

There was no association between detectable pepsin and disease severity, asthma control, exacerbation frequency or FEV₁ (Fig. A). Similar results were found when the model was further adjusted for smoking history, BMI, PPI use (Fig B), eosinophil and neutrophil counts and serum IgE. BAL pH also had no significant association with disease severity (Figure C).

There was no significant difference between barium study result and BAL pepsin; mean (sd) pepsin for positive study 3.4 (1.3) vs. 3.8 (1.4) ng/ml for negative study, $p =$ non-significance (Fig D). When the cohort was divided into positive/negative barium swallow, there was no association between positive barium swallow and ACQ, asthma severity, exacerbation frequency or FEV₁ on either univariate or multivariate analyses.

In a simultaneous multivariable linear regression model, ACQ scores were

significantly related to oral corticosteroid use ($\beta=1.2$, $p=0.006$), inhaled corticosteroid use ($\beta=0.83$, $p<0.001$), but not detectable BAL pepsin ($\beta=0.004$, $p=0.99$).

DISCUSSION:

Research to date, pertaining to the possible utility of BAL pepsin as a marker of aspiration has been undertaken mainly in the areas of acute lung injury, end-stage lung disease, and post lung transplantation^{13,14,23}. It has been shown that detection of pepsin and bile acids in BAL and exhaled breath condensate can be employed to aid identification of lung transplantation recipients with GER-induced aspiration. Elevated levels are associated with acute allograft rejection and/or bronchiolitis obliterans syndrome¹³. The use of pepsin as a surrogate for aspiration and therefore increased risk of rejection has led to its use as a means for justifying anti-reflux surgery in this niche population, with clinical outcomes suggesting a protective role in terms of non-allogenic injury²⁰.

It has long been postulated that there is a link between GER and asthma severity⁷. Despite this there has been a paucity of research specifically looking at airway pepsin as a biomarker of adverse clinical outcome and disease severity in the asthmatic lung. Our results demonstrated a median pepsin concentration of 3.58ng/ml (range 2.53-15.78ng/ml), in the 58.9% of patients demonstrating detectable pepsin, confirming that aspiration does occur in asthmatic patients. Despite its demonstrable presence, pepsin concentration showed no significant association with clinical markers of disease severity or asthma control.

Asthma and GER are known to share potential risk factors, such as smoking and obesity. BAL pepsin levels demonstrated no association with either BMI or smoking history. More importantly, there was no significant difference in pepsin levels when divided according to the presence or absence of GER by barium swallow.

The median pepsin concentration of 3.58ng/ml, when compared to findings in other studies (using similar BAL sampling techniques), was significantly greater than control groups (median 1.1ng/ml), and patients with chronic cough (median 0ng/ml). This was therefore consistent with the presence of micro-aspiration into the lungs of some asthmatics¹³. The levels are below those seen post lung transplantation (median

8.3ng/ml), which is not surprising as lung allograft recipients are regarded as being especially vulnerable to aspiration because of gastroparesis, impaired cough²¹, and dysfunctional mucociliary clearance²².

Pepsin levels however did not exhibit a significant correlation with asthma exacerbation frequency ($p=0.66$). When patients were subdivided into groups by exacerbation frequency (≤ 3 , 4-6 and ≥ 7 exacerbations/year) there was no significant difference in pepsin concentration across the groups (3.27ng/ml, 2.53ng/ml and 3.51ng/ml respectively). There remains the possibility that low-grade exposure to aspiration over a prolonged period of time may still play a role in promoting airway inflammation and increase the risk of future exacerbation, but our study does not suggest that this is associated with poorer asthma control.

Pepsin levels were not significantly different in patients treated with maintenance acid suppression therapy (median, 2.85ng/ml) compared with patients who were untreated (median, 2.79ng/ml $p = ns$). This provides evidence of gastric aspiration even in patients who were treated with maintenance PPI's. Similar results have been previously reported in the post-transplant population¹⁴. This may partially explain why trials examining the potential use of PPI's in asthma have afforded mixed results^{9-11,23}.

In this study we utilized pepsin and barium swallow (with provocation), rather than pH manometry/24hr impedance to assess reflux. Barium swallow (esophagography) maintains a role in the modern assessment of GERD, especially in patients with symptoms severe enough to warrant the consideration of surgical intervention²⁴⁻²⁸. Despite its many limitations, a recent consensus statement from the Society of Abdominal Radiology has recommended that due to its inexpensive and non-invasive nature, in conjunction with its wide availability, that Barium swallow should be considered as a first-line test for the investigation of GERD²⁹. While the sensitivity of the standard barium swallow for the detection of reflux is often quoted as low as 35-50%³⁰, with the addition of provocative manoeuvres the sensitivity of barium swallow approaches that of pH testing^{31,32}. As we were more interested in the role of aspiration, (be it acidic or non-acidic refluxate) we felt that barium swallow (at the time of initial study planning and approval) was an appropriate means to assess for

reflux with the presence of BAL pepsin ultimately defining the presence of aspiration. Our results demonstrated however, no significant relationship between barium swallow and either pepsin concentration or exacerbation frequency, thereby suggesting that Barium swallow did not accurately reflect the presence of aspiration in our cohort. Although we did not assess for nocturnal reflux symptoms, across the entire asthma disease severity there was no observable relationship to the presence of aspiration or the treatment effect of PPI. Furthermore, our study would undoubtedly have been strengthened by performing pH manometry/24hr impedance in our patients and exploring whether or not this test reflects BAL pepsin levels.

Further studies have looked at the effect of PPIs on acidic bile salts as opposed to pepsin. Hou *et al* demonstrated in an epithelial cell model that omeprazole inhibits IL-8 secretion stimulated by exposure to acid and bile salts³³. They demonstrated that acidic bile salts activate the IL-8 promoter through NF-KB and AP-1 DNA binding sites, and that omeprazole inhibits IL-8 production by blocking nuclear translocation of p65, as well as decreased binding of p65, c-jun and c-fos to the IL-8 promoter. These effects occurred independently of the effects on gastric acid secretion, demonstrating a novel mechanism that might contribute to the beneficial effects of PPIs in the treatment of reflux related pulmonary inflammation. The caveat to this finding comes from research published by Pauwels *et al*, in which they examined the effect of gastric aspirates from CF patients being treated with a PPI and found that such aspirates demonstrated an enhanced inflammatory effect (higher IL-8 production) on CF bronchial epithelial cells³⁴. We have recently shown that microbiological growth from gastric juice occurred when gastric juice pH was >4 and that gastric and airway microbiomes of people with CF who reflux are similar, indicating a possible mechanism to explain such observations^{35,36}. As chronic PPI treatment in CF may result in a paradoxically proinflammatory effect in airways, alternative anti-reflux therapies may need to be considered.

Our study has several possible limitations. Having only 17% of our patients designated GINA 5, limits the strengths of our conclusions. Furthermore, we did not assess another commonly cited asthma outcome measure; bronchial hyper-reactivity. This would undoubtedly have been of interest, and would have enhanced our findings.

There also exists a plausible alternative mechanism for reflux-mediated exacerbation of asthma in the form of vagally mediated, reflexive bronchospasm. Acidic-stimulation of esophageal mucosal receptors giving rise to vagally mediated reflex bronchospasm. Mansfield and colleagues noted that the total respiratory resistance increased by 10% in asthmatics with a positive Bernstein test (acid perfusion test) after esophageal acid stimulation³⁷. Wright and colleagues noted significant decreased airflow and arterial oxygen saturation before and after esophageal acid perfusion³⁸. Atropine pretreatment abolished these findings, providing evidence for an acid-induced vagally mediated esophagobronchial reflex. Therefore, although our results show definitive aspiration (as denoted by the presence of pepsin in the BAL of our cohort); the possibility remains for worsening of asthma symptoms without aspiration into the lungs, but simply into the esophagus, potentially via this alternative mechanism.

We have demonstrated that pepsin, and therefore aspiration occurs in the asthmatic lung. However, there does not seem to be a clear link between its presence and disease severity. It may be that in asthmatics, pepsin in itself is not an accurate biomarker of the inflammatory airway process that results from exposure to chronic aspiration. Alternatively, it may be that chronic exposure over time to low levels of aspirate is sufficient to drive an inflammatory response causing subsequent differences in clinical severity. Further studies at cellular level are needed to examine the underlying pathways involved and ascertain whether the presence of pepsin is indeed a marker of a pro-inflammatory state. However, based on the lack of clearly demonstrable difference between pepsin levels in patients with differing asthma severity, it may ultimately be that the impact of aspiration on disease severity at a clinical level has been over stated.

ACKNOWLEDGMENTS:

DM had access to all data in the study and takes responsibility it's integrity and the accuracy of data analysis. EH, CW, SP, AS, JP, SL, PO'B, JE, BP, MM and JMacS contributed substantially to study design, data analysis and interpretation, and writing of the manuscript. We thank Professor Elizabeth Juniper for permission to use the ACQ-7.

REFERENCES:

1. GINA Report, Global strategy for asthma management and prevention- 2016. <http://www.ginasthma.org>
2. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. *Thorax* 2014;69 (Suppl 1):1–192.□
3. National Heart Lung and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, 2007.□
4. Tommelein E, Mehuys E, Van Tongelen I, et al. Accuracy of the Medication Adherence Report Scale (MARS-5) as a quantitative measure of adherence in inhalation medication in patients with COPD. *Ann Pharmacother* 2014;48:589-95
5. D'Arcy S, MacHale E, Seheult J, et al. A method to assess adherence in inhaler use through analysis of acoustic recordings of inhaler events. *PLoS ONE* 2014;9:e98701.□
6. Harnett CM, Hunt EB, Bowen BR et al. A study to assess inhaler technique and its potential impact on asthma control in patients attending an asthma clinic. *J Asthma*. 2014 May;51(4):440-5.
7. Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. *Am J Respir Crit Care Med*. 2012 Feb 15;185(4):356-62.
8. Cazzola M, Calzetta L, Bettoncelli G, et al. Asthma and comorbid medical illness. *Eur Respir J*. 2011 Jul;38(1):42-9.
9. Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. *Am J Respir Crit Care Med*. 2006 May 15;173(10):1091-7.

10. Kiljander TO, Junghard O, Beckman O, et al. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. *Am J Respir Crit Care Med*. 2010 May 15;181(10):1042-8.
11. Mastrorade JG, Anthonisen NR, Castro M, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. *N Engl J Med*. 2009 Apr 9;360(15):1487-99.
12. Ward C, Ryan V, Pearson J. Susceptibility to exacerbation in COPD. *N Engl J Med*. 2010 Dec 30;363(27):2671; author reply
13. Stovold R, Forrest IA, Corris PA, et al. Pepsin, a biomarker of gastric aspiration in lung allografts: a putative association with rejection. *Am J Respir Crit Care Med*. 2007 Jun 15;175(12):1298-303.
14. Ward C, Forrest IA, Brownlee IA, et al. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. *Thorax*. 2005 Oct;60(10):872-4.
15. Rothenberg SS, Bratton D. The effects of laparoscopic Nissen fundoplication to enhance pulmonary function in the treatment of a patient with severe asthma and gastroesophageal reflux disease. *J Allergy Clin Immunol*. 2008 Apr;121(4):1069-70.
16. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. *Eur Respir J*. 1999 Oct;14(4):902-7.
17. American Thoracic Society/European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med* 2005;171:912– 930.
18. Baker ME, Einstein DM, Herts BR et al. Gastroesophageal Reflux Disease: Integrating the Barium Esophagram before and after Antireflux Surgery *Radiology* (2007) May;243(2):329-39
19. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. American Thoracic Society Committee on BAL in Interstitial Lung Disease. *Am J Respir Crit Care Med*. 2012 May 1;185(9):1004-14.
20. Fisichella PM, Davis CS, Lundberg PW, et al. The protective role of laparoscopic antireflux surgery against aspiration of pepsin after lung transplantation. *Surgery*. 2011 Oct;150(4):598-606.

21. Higenbottam T, Jackson M, Woolman P, et al. The cough response to ultrasonically nebulized distilled water in heart- lung transplantation patients. *Am Rev Respir Dis* 1989;140:58–61.
22. Laube BL, Karmazyn YJ, Orens JB, et al. Albuterol improves impaired mucociliary clearance after lung transplantation. *J Heart Lung Transplant* 2007;26:138–144.
23. Leggett JJ, Johnston BT, Mills M, et al. Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. *Chest*. 2005 Apr;127(4):1227–31.
24. Zarzour JG, Sanyal R, Canon CL. Evaluation of gastroesophageal reflux and its complications. *Appl Radiol* 2014;:44–9.
25. Baker ME, Einstein DM. Barium esophagram: does it have a role in gastroesophageal reflux disease? *Gastroenterol Clin North Am* 2014;43:47–68.
26. Levine MS, Rubesin SE. History and Evolution of the Barium Swallow for Evaluation of the Pharynx and Esophagus. *Dysphagia* Published Online First: 18 January 2017. doi:10.1007/s00455-016-9774-y
27. Jobe BA, Richter JE, Hoppo T, et al. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. *J Am Coll Surg* 2013;217:586–97.
28. Lacy BE, Weiser K, Chertoff J, et al. The diagnosis of gastroesophageal reflux disease. *Am J Med* 2010;123:583–92.
29. Levine MS, Carucci LR, DiSantis DJ, et al. Consensus Statement of Society of Abdominal Radiology Disease-Focused Panel on Barium Esophagography in Gastroesophageal Reflux Disease. *AJR Am J Roentgenol* 2016;207:1009–15.
30. Saleh CMG, Smout AJPM, Bredenoord AJ. The diagnosis of gastro-esophageal reflux disease cannot be made with barium esophagograms. *Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc* 2015;27:195–200.
31. Fiorentino E, Matranga D, Pantuso G, et al. Accuracy of the water-siphon test associated to barium study in a high prevalence gastro-oesophageal reflux disease population: a novel statistical approach. *J Eval Clin Pract* 2010;16:550–5.
32. Thompson JK, Koehler RE, Richter JE. Detection of gastroesophageal reflux: value of barium studies compared with 24-hr pH monitoring. *AJR Am J Roentgenol* 1994;162:621–6.

33. Hou X, Zhang X, Yu C, et al. In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through its effects on nuclear factor- κ B and activator protein-1. *Gut*. 2014 63(7):1042-1052
34. Pauwels A, Verleden S, Farre R, et al. The effect of gastric juice on interleukin-8 production by cystic fibrosis primary bronchial epithelial cells. *J Cyst Fibros*. 2013 12(6):700-5
35. Jones R, Pearson J, Ward C. Functional Dyspepsia. *N Engl J Med*. 2016 Mar 3;374(9):895. doi: 10.1056/NEJMc1515497#SA2
36. Al-Momani H, Perry A, Stewart CJ et al. Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients. *Sci Rep*. 2016 Jun 1;6:26985. doi: 10.1038/srep26985
37. Mansfield LE. Role of vagus nerve in airway narrowing in esophageal acid provocation. *Ann Allergy*. 1981;47:431-434.
38. Wright RA. Acid induced esophageal bronchial cardiac reflexes in humans. *Gastroenterology*. 1990;47:431-434.

TABLE 1. PATIENT CHARACTERISTICS

(Mean $\pm$ Standard deviation)

	N=	ACQ- 7 score	FEV ₁ (%predicted)	Blood Eosinophil count(10 ⁹ /ml)	BMI (kg/m ²)	pH	Pepsin (ng/ml)	FeNO (ppb)	Exacerbations/ year
GINA 1	11	1.2 (0.7)	80.9 (10.8)	0.22 (0.22)	26.16 (5.33)	6.16 (0.30)	5.88 (4.14)	37.8 (32.1)	2.18 (1.72)
GINA 2	17	1.1 (0.6)	90.0 (13.6)	0.29 (0.23)	25.76 (3.91)	6.22 (0.20)	4.68 (1.55)	30.2 (23.5)	3.00 (3.92)
GINA 3	17	1.9 (1.0)	86.7 (20.6)	0.33 (0.39)	27.54 (6.87)	6.16 (0.34)	4.45 (1.61)	24.1 (10.6)	3.63 (2.36)
GINA 4	20	2.7 (0.7)	75.5 (17.1)	0.20 (0.17)	29.61 (6.45)	6.23 (0.37)	4.43 (1.39)	20.2 (14.3)	4.75 (3.65)
GINA 5	13	4.2 (1.1)	47.7 (20.2)	0.35 (0.32)	31.13 (6.16)	6.33 (0.44)	4.02 (1.52)	32.1 (43.4)	8.23 (4.60)

A. **B.** **C.** **D.**

Abbreviation List

BAL: bronchoalveolar lavage

BMI: body mass index

FeNO: fractional exhaled nitric oxide

FEV₁: forced expiratory volume in one second

GER: gastro-esophageal reflux

Immune cells in BAL fluid

e-Figure 1. BAL Immune cell profile of asthmatic patient cohort. n= 78.